Lurasidone in schizophrenia: New information about dosage and place in therapy

Advances in Therapy

Volumn 29, Issue 10, 2012, Pages 815-825

  Citrome, Leslie ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

Dosing; Efficacy; Lurasidone; Psychiatry; Safety; Schizophrenia; Tolerability

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; HALOPERIDOL; ILOPERIDONE; LURASIDONE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AKATHISIA; ANXIETY; AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG PACKAGING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPESTHESIA; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NOSE OBSTRUCTION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

EID: 84872118728     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0052-6     Document Type: Review

References (25)

1. United States Food and Drug Administration. FDA approves Latuda to treat schizophrenia in adults. Press release, October 28, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231512.htm. Accessed Jun 20 2012.
2. Sunovion Pharmaceuticals Canada Inc. Sunovion Pharmaceuticals Canada Inc. announces Health Canada approval of once-daily LATUDA™ (lurasidone HCl) for the treatment of patients with schizophrenia. Press release, June 15, 2012. Available at: http://www.sunovion.ca/news/pressReleases/20120615.pdf. Accessed Jun 20 2012.
3. Sunovion Pharmaceuticals Inc. Latuda: US Package Insert for Latuda (lurasidone HCl) tablets for oral use. May 2012. Available at: http://www.latuda.com/LatudaPrescribingInformation.pdf. Accessed Sept 5 2012.
4. Sunovion Pharmaceuticals Canada Inc. Latuda: Product Monograph for Latuda (lurasidone HCl) 40 mg, 80 mg and 120 mg film-coated tablets. 18 June 2012. Available at: http://www.sunovion. ca/monographs/latuda.pdf. Accessed Jun 20 2012.
5. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917-28.
6. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65:189-210.
7. Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses. 2011;4:251-7.
8. Kantrowitz JT, Citrome L. Lurasidone for schizophrenia: what's different? Expert Rev Neurother. 2012;12:265-73.
9. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18:1715-26.
10. Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther. 2009;26:739-48.
11. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:829-36.
12. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168:957-67.
13. Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2012. [Epub ahead of print].
14. Loebel A, Cucchiaro J, Pikalov A, et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week, PEARL 3 trial. Neuropsychopharmacology. 2011;35(Suppl. 1):S313-4.
15. United States Food and Drug Administration. Drug approval package. Latuda (lurasidone hydrochloride) tablets. Available at: www.accessdata.fda.gov/ drugsatfda-docs/nda/2010/200603Orig1s000TOC.cfm. Accessed Jun 20 2012.
16. Potkin S, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132:101-7.
17. Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses. 2012;6:76-85.
18. th Annual Meeting; May 5-9, 2012; Philadelphia, PA.
19. Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27:165-76.
20. th Annual Meeting; May 5-9, 2012; Philadelphia, PA.
21. th Annual Meeting; May 14-18, 2011; Honolulu, HI.
22. Citrome L. Iloperidone, asenapine and lurasidone. A brief overview of three new second-generation antipsychotics. Postgrad Med. 2011;123(2):153-62.
23. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13:1599-613.
24. th Annual Meeting; May 5-9, 2012; Philadelphia, PA.
25. th Annual Meeting; May 5-9, 2012; Philadelphia, PA.